An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice

作者：Fu Ying^*; Silverstein Shana; McCutcheon Justine N.; Dyba Marcin; Nath Raghu G.; Aggarwal Monika; Coia Heidi; Bai Angela; Pan Jishen; Jiang Jiji; Kallakury Bhaskar; Wang Hongkun; Zhang Yu-Wen; Giaccone Giuseppe; He Aiwu Ruth; Chung Fung-Lung^*

来源：Hepatology, 2018, 67(1): 159-170.

DOI：10.1002/hep.29380

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, mainly because of its poor prognosis. A valid mechanism-based prognostic biomarker is urgently needed. -hydroxy-1,N-2-propanodeoxyguanosine (-OHPdG) is an endogenously formed mutagenic DNA adduct derived from lipid peroxidation. We examined the relationship of -OHPdG with hepatocarcinogenesis in two animal models and its potential role as a prognostic biomarker for recurrence in HCC patients. Bioassays were conducted in xeroderma pigmentosum group A knockout mice and diethylnitrosamine-injected mice, both prone to HCC development. -OHPdG levels in the livers of these animals were determined. The effects of antioxidant treatments on -OHPdG and hepatocarcinogenesis were examined. Using two independent sets of HCC specimens from patients, we examined the relationship between -OHPdG and survival or recurrence-free survival. -OHPdG levels in liver DNA showed an age-dependent increase and consistently correlated with HCC development in all three animal models. Theaphenon E treatment significantly decreased -OHPdG levels in the liver DNA of xeroderma pigmentosum group A knockout mice and remarkably reduced HCC incidence in these mice to 14% from 100% in the controls. It also effectively inhibited HCC development in the diethylnitrosamine-injected mice. Using clinical samples from two groups of patients, our study revealed that higher levels of -OHPdG are strongly associated with low survival (P < 0.0001) and low recurrence-free survival (P = 0.007). Conclusion: These results support -OHPdG as a mechanism-based, biologically relevant biomarker for predicting the risk of HCC and its recurrence. (Hepatology 2018;67:159-170).

• 出版日期2018-1